Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.5 EUR | 0.00% | 0.00% | 0.00% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- With an expected P/E ratio at 30.29 and 22.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.14 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 33.23B | - | ||
+11.85% | 79.93B | B | ||
-7.69% | 43.46B | A- | ||
+14.54% | 18.7B | B | ||
+6.60% | 11.26B | A- | ||
-23.89% | 9.96B | B | ||
-11.57% | 9.55B | - | ||
+0.38% | 8.76B | A- | ||
-3.72% | 8.41B | C- | ||
+5.43% | 7.97B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DD Stock
- DOWCP Stock
- Ratings DuPont de Nemours